Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 255

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 255
---
. Rolfe and Mr. Patel is independent under the applicable Nasdaq listing standards
and is a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act.

Our Compensation Committee’s
main function is to oversee our compensation structure, policies and programs and to review the processes and procedures for the consideration
and determination of director and executive compensation. The Compensation Committee’s responsibilities include, among other things:

| ● | recommending to the board                                                                             
 of directors goals and objectives, non-equity compensation, and equity grants of all senior officers; |

| ● | recommending to the board                                                                                      
 of directors goals and objectives, non-equity compensation, and equity grants for the Chief Executive Officer; |

| ● | recommending to the board                                                 
 of directors non-equity compensation and equity grants for the directors; |

| ● | reviewing and discussing                                                                                 
 with the board of directors corporate succession plans for the Chief Executive Officer and key officers; |

| ● | reviewing and discussing                                        
 with management its talent development and related initiatives; |

| ● | assisting the board of                                                                                                                    
 directors with its oversight of our strategies, programs, and initiatives related to employee health, safety, and well-being, engagement, 
 pay equity, and diversity and inclusion;                                                                                                  |

| ● | selecting independent compensation                                                                                          
 consultants and assessing whether there are any conflicts of interest with any of the Compensation Committee’s compensation 
 advisors;                                                                                                                   |

| ● | reviewing and recommending                                                                                                           
 to the board of directors employment agreements, severance arrangements and change-of-control agreements or provisions for executive 
 officers and other senior management, as appropriate; and                                                                            |

| ● | reviewing the policies                              
 relating to compensation and benefits of employees. |

Nominating and Corporate Governance Committee

The members of our nominating
and corporate governance committee are Dr. Rolfe, Ms. LaPorte and Mr. Byrnes. Dr. Rolfe serves as the chairperson of the committee. Our
board of directors has determined that each of Dr. Rolfe, Ms. LaPorte and Mr. Byrnes is independent under the applicable Nasdaq listing
standards.

<div align='center'>148</div>

The nominating and corporate
governance committee’s main function is to consider candidates for board membership and oversee our corporate governance policies,
reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board
of directors. The nominating and corporate governance committee’s responsibilities include,